Kathleen Harnden

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 695 citations · Full text

Medicine, Oncology, Pharmacology +15

Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?

Debu Tripathy, Kathleen Harnden, Kimberly Blackwell et al. · BMC Medicine · 2014 · 53 citations · Full text

Medicine, Bioinformatics, Oncology +17

Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

Aditya Bardia, François‐Clément Bidard, Patrick Neven et al. · Cancer Research · 2023 · 42 citations

Medicine, Endocrinology, Oncology +17

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

Komal Jhaveri, Elgene Lim, Rinath Jeselsohn et al. · Journal of Clinical Oncology · 2024 · 38 citations · Full text

Medicine, Oncology, Pharmacology +15

A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.

Komal Jhaveri, Elgene Lim, Erika Hamilton et al. · Journal of Clinical Oncology · 2021 · 36 citations

Medicine, Oncology, Pharmacology +13